间充质干细胞在急性肺损伤治疗中的研究进展

Research progress of mesenchymal stem cells in treatment of acute lung injury

急性肺损伤(acute lung injure,ALI)是在ICU中常见的危重症,通常是由多种直接或者间接损伤因素所导致的,具有较高的死亡率,而急性呼吸窘迫综合征(acute respiratory distress syndrome,ARDS)通常认为是ALI的严重阶段。目前临床上对于ALI/ARDS的治疗主要是通过呼吸末正压通气的方式,但是这种方式仍然需要通过不断优化来提高存活率。间充质干细胞(mesenchymal stem cells,MSCs)治疗作为一种非侵入式的、新型的治疗方法,在动物实验中已经取得了很好的疗效,并且已经开始研究MSCs在临床实际治疗时的细节。因此,本文将对阐述MSCs在ALI治疗机制等方面的研究,以期为临床治疗奠定基础。

Acute lung injury(ALI)is a common critical disease in ICU.It is usually caused by a variety of direct or indirect injury factors,and has a high mortality.Acute respiratory distress syndrome(ARDS)is usually considered as a severe stage of ALI.At present,the treatment of ALI/ARDS is mainly positive end-of-breath pressure ventilation,but this method still needs to be optimized to improve survival rate.Mesenchymal stem cell therapy,as a non-invasive,new treatment method,has achieved good results in animal experiments,and details of stem cell therapy in clinical practice are under investigation.Therefore,the research on the mechanism of stem cell treatment for ALI will lay a foundation for clinical treatment.